Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Aaron Cleveland

Family Medicine Sacramento, CA Medical Doctor

NPI 1497829147 CMS profile 21865

2020 J St, Sacramento, CA 95811

Open in the dashboard

General payments

$103,242

283 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Aaron Cleveland of Sacramento, CA is reported in the CMS Open Payments database as having received $103,242 across 283 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16,219 46
2024 General $15,511 26
2023 General $12,551 36
2022 General $17,885 43
2021 General $10,760 39
2020 General $8,858 26
2019 General $21,459 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aaron Cleveland
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Aaron Cleveland were reported at $16,219. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Aaron Cleveland Family Medicine median Middle half National median
2019 $21,459 $150 $41–$543 $163
2020 $8,858 $120 $32–$415 $114
2021 $10,760 $137 $35–$551 $132
2022 $17,885 $137 $37–$512 $149
2023 $12,551 $149 $42–$545 $160
2024 $15,511 $156 $44–$560 $164
2025 $16,219 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Gilead Sciences, Inc. $102,684 257 payments
  2. Novo Nordisk Inc $109 5 payments
  3. Janssen Pharmaceuticals, Inc $68 3 payments
  4. Hologic, LLC $49 2 payments
  5. Alkermes, Inc. $46 2 payments
  6. Exact Sciences Corporation $28 1 payment
  7. ViiV Healthcare Company $26 1 payment
  8. AbbVie, Inc. $25 1 payment
  9. Cipher Pharmaceuticals US LLC $24 1 payment
  10. Xeris Pharmaceuticals, Inc. $23 1 payment
  11. Other $160 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $88,770 49 payments
  2. Travel and Lodging $8,385 35 payments
  3. Food and Beverage $6,087 199 payments
Products named General payments · program years 2019–2025
  1. Epclusa $89,407 121 payments
  2. Yeztugo $122 1 payment
  3. INVEGA SUSTENNA $68 3 payments
  4. Aptima $49 2 payments
  5. VIVITROL $46 2 payments
  6. Wegovy $46 2 payments
  7. Ozempic $40 2 payments
  8. Cologuard Collection Kit $28 1 payment
  9. APRETUDE $26 1 payment
  10. MAVYRET $25 1 payment
  11. Other $277 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

901

Median for Family Practice: 1,826

Drug cost

$97,552

Median for Family Practice: $120,094

Branded share of claims

23.2%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Abilify Maintena Aripiprazole Brand 12 $35,612
Rexulti Brexpiprazole Brand 13 $19,343
Ozempic Semaglutide Brand 11 $12,214
Eliquis Apixaban Brand 18 $10,274
Spiriva Respimat Tiotropium Bromide Brand 13 $6,693
Mesalamine Dr Mesalamine Brand 11 $3,064
Aripiprazole Generic 16 $1,727
Progesterone Progesterone, Micronized Brand 13 $856
Albuterol Sulfate Hfa Albuterol Sulfate Brand 39 $785
Olanzapine Generic 23 $765

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Epclusa
  • Gilead Sciences, Inc. $10,810
$10,810 — —
Ozempic
  • Novo Nordisk Inc $23
$23 11 —
NURTEC ODT
  • PFIZER INC. $7
$7 — —
ZAVZPRET
  • PFIZER INC. $7
$7 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

283 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record